- Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST Professor Joung Ho Kim join a pioneering collaboration in precision oncology. SEOUL, South Korea , Nov. 5, 2024 /PRNewswire/ -- On November 4 , 2024, J INTS BIO hosted a significant MOU signing ceremony at Baekyangnuri Plaza, Yonsei University , unveiling a groundbreaking AI-driven collaboration to revolutionize cancer treatment.
This ambitious alliance unites leading institutions, including Yonsei University College of Medicine's DAAN Cancer Research Institute, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Korea Research Institute of Chemical Technology (KRICT), and KAIST. The event featured a distinguished lineup, with Yuhan Corporation CEO Wook Je Cho, National Assembly Representative Seong Hoon Park , and KAIST's Professor Joung Ho Kim , a prominent member of the National AI Committee, highlighting the extensive support from both government and industry sectors. Precision Medicine Redefined: AI Meets Multi-Omics J INTS BIO is at the forefront of developing personalized lung cancer therapies through the integration of artificial intelligence and multi-omics technology.
Multi-omics offers a comprehensive approach to disease biology by combining genomics, transcriptomics, metabolomics, and proteomics. Using AI and national supercomputing infrastructure, the project aims to enhance drug efficacy prediction and minimize toxicity, addressing the critical challenges that plagu.
